JPWO2022122973A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022122973A5 JPWO2022122973A5 JP2023532452A JP2023532452A JPWO2022122973A5 JP WO2022122973 A5 JPWO2022122973 A5 JP WO2022122973A5 JP 2023532452 A JP2023532452 A JP 2023532452A JP 2023532452 A JP2023532452 A JP 2023532452A JP WO2022122973 A5 JPWO2022122973 A5 JP WO2022122973A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- set forth
- bispecific antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000000833 heterodimer Substances 0.000 claims 2
- 102000045108 human EGFR Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 1
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 1
- 241000235058 Komagataella pastoris Species 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 230000006107 tyrosine sulfation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20213166.0 | 2020-12-10 | ||
| EP20213166 | 2020-12-10 | ||
| PCT/EP2021/085079 WO2022122973A1 (en) | 2020-12-10 | 2021-12-09 | Antibodies that bind gamma-delta t cell receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501403A JP2024501403A (ja) | 2024-01-12 |
| JP2024501403A5 JP2024501403A5 (https=) | 2024-12-17 |
| JPWO2022122973A5 true JPWO2022122973A5 (https=) | 2024-12-17 |
Family
ID=73793117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023532452A Pending JP2024501403A (ja) | 2020-12-10 | 2021-12-09 | ガンマ－デルタｔ細胞受容体に結合する抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230303694A1 (https=) |
| EP (1) | EP4259660A1 (https=) |
| JP (1) | JP2024501403A (https=) |
| KR (1) | KR20230157933A (https=) |
| CN (1) | CN116888153A (https=) |
| AU (1) | AU2021395439A1 (https=) |
| CA (1) | CA3200826A1 (https=) |
| IL (1) | IL303045A (https=) |
| MX (1) | MX2023006832A (https=) |
| WO (1) | WO2022122973A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116323667A (zh) | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| EP4292610A1 (en) * | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| WO2024200573A1 (en) | 2023-03-27 | 2024-10-03 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| TW202519261A (zh) | 2023-07-27 | 2025-05-16 | 荷蘭商拉法醫療公司 | 用於治療癌症之結合γ-δ T細胞受體之抗體 |
| WO2025128615A1 (en) * | 2023-12-12 | 2025-06-19 | Seagen Inc. | Multispecific egfr antibodies and use in the treatment of cancer |
| TW202535922A (zh) * | 2023-12-18 | 2025-09-16 | 美商思進公司 | 治療ｅｇｆｒ突變癌症之方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| EP3129404B1 (en) * | 2014-04-10 | 2026-01-28 | LAVA Therapeutics N.V. | Immunoglobulins binding human vgamma9vdelta2 t cell receptors |
| WO2020060406A1 (en) | 2018-09-19 | 2020-03-26 | Lava Therapeutics B.V. | Novel bispecific antibodies for use in the treatment of hematological malignancies |
| CN113993893A (zh) * | 2019-02-01 | 2022-01-28 | 拉法医疗有限公司 | 新cd40结合抗体 |
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
-
2021
- 2021-12-09 IL IL303045A patent/IL303045A/en unknown
- 2021-12-09 CN CN202180090574.0A patent/CN116888153A/zh active Pending
- 2021-12-09 CA CA3200826A patent/CA3200826A1/en active Pending
- 2021-12-09 MX MX2023006832A patent/MX2023006832A/es unknown
- 2021-12-09 WO PCT/EP2021/085079 patent/WO2022122973A1/en not_active Ceased
- 2021-12-09 AU AU2021395439A patent/AU2021395439A1/en active Pending
- 2021-12-09 EP EP21824387.1A patent/EP4259660A1/en active Pending
- 2021-12-09 JP JP2023532452A patent/JP2024501403A/ja active Pending
- 2021-12-09 KR KR1020237023004A patent/KR20230157933A/ko active Pending
-
2023
- 2023-06-09 US US18/332,165 patent/US20230303694A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10676535B2 (en) | Anti c-Met antibodies | |
| JP6742245B2 (ja) | 多重特異性抗体 | |
| JP7600328B2 (ja) | ＰＤ－１とＴＧＦ－ｂｅｔａを標的とした四価二重特異性抗体、その製造方法および用途 | |
| CN106573986A (zh) | 多特异性抗体 | |
| JP2018537966A5 (https=) | ||
| CN115057936A (zh) | 异源二聚体多特异性抗体形式 | |
| JP2021533159A5 (https=) | ||
| US20240368311A1 (en) | Bispecific antigen binding construct | |
| JP7526493B2 (ja) | Ｌｒｉｇ－１タンパク質に特異的な結合分子及びその用途 | |
| CN106397599B (zh) | 二价双特异性抗体杂交蛋白的表达和制备方法 | |
| WO2017143840A1 (zh) | 多价多特异性抗体及免疫杂合蛋白的表达和制备方法 | |
| WO2014063368A1 (zh) | 抗人死亡受体5胞外区的人源化单克隆抗体 | |
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JP2021512613A5 (https=) | ||
| JPWO2022122973A5 (https=) | ||
| JPWO2022102768A5 (https=) | ||
| JPWO2022008646A5 (https=) | ||
| JPWO2021190622A5 (https=) | ||
| RU2024136797A (ru) | Вариантные антитела, которые связывают гамма-дельта-т-клеточные рецепторы | |
| CN111479827A (zh) | 结合hERG1和hERG1/整联蛋白β1的单特异性和双特异性抗体 | |
| JPWO2022180271A5 (https=) | ||
| JPWO2019157308A5 (https=) | ||
| JP2022504392A5 (https=) | ||
| WO2025167974A1 (zh) | 多特异性抗体或抗原结合片段 | |
| US20240301061A1 (en) | Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use |